Brief: Scilex Holding Says FDA Granted Fast Track Designation For Investigational Drug Candidate SP-103
31/08/2022 04:24
Aug 30 (Reuters) -
* SCILEX HOLDING COMPANY - FDA HAS GRANTED FAST TRACK
DESIGNATION
FOR ITS INVESTIGATIONAL DRUG AND DEVICE PRODUCT CANDIDATE,
SP-103
Source text for Eikon: ID:nGNX3NtPdF
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20